新型口服抗凝药用于肥厚型心肌病合并房颤患者卒中一级预防
该研究基于韩国健康保险审查评估院数据库,纳入2013至2016年2397例无卒中、颅内出血或消化道出血史的肥厚型心肌病合并非瓣膜性房颤口服抗凝患者(华法林992例,NOACs 1405例),采用倾向评分逆概率加权平衡协变量。平均随访1.6年,NOAC组缺血性卒中、颅内出血、消化道出血、死亡及复合结局发生率均显著低于华法林组,且不同NOAC剂量及高危亚组趋势一致。
要点
- NOACs较华法林显著降低缺血性卒中风险(HR 0.47,95%CI 0.32-0.68)。
- NOACs较华法林显著降低颅内出血、消化道出血及死亡风险。
- 不同NOAC剂量及高危亚组中NOACs获益趋势一致。
核心结论
- 在真实世界亚洲肥厚型心肌病合并房颤患者中,NOACs用于卒中一级预防的疗效和安全性优于华法林。
研究设计与样本
- 基于韩国健康保险审查评估院数据库的回顾性队列研究,纳入2397例肥厚型心肌病合并非瓣膜性房颤口服抗凝且无卒中、颅内出血或消化道出血史的患者(华法林992例,NOACs 1405例),采用倾向评分逆概率加权平衡协变量。
主要发现
- 平均随访1.6年,NOAC组与华法林组每100人年事件率分别为:缺血性卒中2.8 vs 5.0,颅内出血0.5 vs 1.3,消化道出血2.3 vs 3.0,死亡3.0 vs 5.1,复合结局7.5 vs 12.5。
- NOACs较华法林显著降低缺血性卒中(HR 0.47,95%CI 0.32-0.68)、颅内出血(HR 0.31,95%CI 0.14-0.69)、消化道出血(HR 0.62,95%CI 0.40-0.96)、死亡(HR 0.45,95%CI 0.31-0.65)及复合结局(HR 0.48,95%CI 0.38-0.61)风险。
- 不同NOAC剂量及各种高危亚组中趋势一致,个体NOAC分析显示所有NOACs均与较低的缺血性卒中和复合结局风险相关。
临床怎么用
- 对于肥厚型心肌病合并房颤且无卒中、颅内出血或消化道出血史的患者,可优先考虑NOACs而非华法林进行卒中一级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Hypertrophic cardiomyopathy patients with atrial fibrillation are at increased risk of stroke, and anticoagulation is strongly recommended. However, limited data are available regarding the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) for primary prevention of stroke. Methods- Using the Korean Health Insurance Review and Assessment Service database, we identified 2397 patients with hypertrophic cardiomyopathy and nonvalvular atrial fibrillation on oral anticoagulation from 2013 to 2016 without history of ischemic stroke, intracranial hemorrhage (ICH), or gastrointestinal bleeding (992 on warfarin and 1405 on NOACs). Inverse probability of treatment weighting with propensity scores was used to balance covariates between treatment groups. Risk for ischemic stroke, ICH, gastrointestinal bleeding, death, and their composite outcome associated with NOAC use was assessed with warfarin use as the reference. Results- During a mean follow-up of 1.6 years, the incidence rates of ischemic stroke, ICH, gastrointestinal bleeding, death, and composite outcome were all significantly lower in the NOAC than in the warfarin group (stroke, 2.8 versus 5.0; ICH, 0.5 versus 1.3; gastrointestinal bleeding, 2.3 versus 3.0; death, 3.0 versus 5.1; composite, 7.5 versus 12.5 events per 100 person-years). NOACs were associated with significantly lower risks of ischemic stroke (hazard ratio [HR], 0.47; 95% CI, 0.32-0.68), ICH (HR, 0.31; 95% CI, 0.14-0.69), gastrointestinal bleeding (HR, 0.62; 95% CI, 0.40-0.96), death (HR, 0.45; 95% CI, 0.31-0.65), and the composite outcome (HR, 0.48; 95% CI, 0.38-0.61) than warfarin. The same trend was observed regardless of the NOAC dose and across various high-risk subgroups. In analysis of individual NOACs, all NOACs were associated with lower risks of ischemic stroke and composite outcome. Conclusions- NOACs showed superior effectiveness and safety versus warfarin in the primary prevention of stroke versus warfarin in real-world Asian hypertrophic cardiomyopathy with atrial fibrillation.
引用
- Lee HJ, Kim HK, Jung JH, et al. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation. Stroke. 2019. PMID: 31340730. doi:10.1161/STROKEAHA.119.026048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。